A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Swetha Kambhampati(Johns Hopkins University), Charalambos Andreadis(University of California, San Francisco), Teresa Ta(University of California Davis Medical Center), Akshay Sudhindra(Atara Biotherapeutics (United States)), Joseph M. Tuscano(University of California Davis Medical Center), Weiyun Z. Ai(City College of San Francisco), Jesika Reiner(University of California San Diego), Erika Crawford(University of California Davis Medical Center), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Charlie Aoun(University of California, San Francisco), Diem Le(University of California Davis Medical Center), Bita Fakhri(University of California, San Francisco), Michelle Padilla(University of California San Diego), Matthew J. Wieduwilt(Atrium Health Wake Forest Baptist), Jimmy J. Hwang(University of California, San Francisco), Michelle Martinelli(University of California, San Francisco)
Blood
November 13, 2019
10.1182/blood-2019-123279
Cited by 0

Related Papers

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523